An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy

Abstract excerpt

BACKGROUND: Over half of colorectal cancers (CRCs) are hard-wired to RAS/RAF/MEK/ERK pathway oncogenic signaling. However, the promise of targeted therapeutic inhibitors, has been tempered by disappointing clinical activity, likely due to complex resistance mechanisms that are not well understood. This study aims to investigate MEK inhibitor-associated resistance signaling and identify subpopulation(s) of CRC...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Colorectal Cancer Treatments and Studies
• Share to Genetic factors in colorectal cancer
• Share to Melanoma and MAPK Pathways